<DOC>
	<DOCNO>NCT00148798</DOCNO>
	<brief_summary>The purpose trial investigate efficacy cetuximab combination chemotherapy comparison chemotherapy alone patient advance non small cell lung cancer receive prior chemotherapy . Overall survival take primary measure efficacy .</brief_summary>
	<brief_title>Study Cisplatin/Vinorelbine +/- Cetuximab First-line Treatment Advanced Non Small Cell Lung Cancer ( FLEX )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Diagnosis histologically cytologically confirm NSCLC , stage IIIb document malignant pleural effusion stage IV Immunohistochemical evidence EGFR expression tumor tissue Presence least 1 bidimensionally measurable index lesion , whereby index lesion must lie irradiated area Previous exposure monoclonal antibody , signal transduction inhibitor EGFRtargeting therapy Previous chemotherapy NSCLC Documented symptomatic brain metastasis Superior vena cava syndrome contraindicate hydration Previous malignancy last 5 year except basal cell carcinoma skin preinvasive carcinoma cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cetuximab</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Cisplatin/vinorelbine</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Erbitux</keyword>
</DOC>